Peculiarities of polyvascular disease and the diagnostic significance of the ankle-brachial index in patients with coronary artery disease: results from the real-world registry KAMMA (Clinical registry on patient population with polyvascular disease in the Russian Federation and Eurasian countries)
https://doi.org/10.15829/1560-4071-2024-5837
EDN: AZMGQZ
Abstract
Aim. To investigate the prevalence and characteristics of polyvascular disease in the Eurasian region's population with one or more previously established locations of atherosclerotic arterial damage, and to evaluate the diagnostic importance of the ankle-brachial index (ABI) as a marker for polyvascular disease (PVD).
Material and methods. A total of 1837 patients were included in the main branch of the KAMMA registry (patients with PVD), among which 91,6% had coronary artery disease (CAD) (n=1683). For further analysis, the group of patients with CAD was combined with 1222 patients included in the second branch of the registry — KAMMA-cardio, forming a patient population (n=2905), in which all patients had verified CAD. The mean age of patients was 66,0 [59,0; 72,0] years, with 60,3% being male. Peripheral arteries was assessed using ultrasound examination.
Results. PVD was present in 95,6% of patients with coronary atherosclerosis: dual-region involvement was observed in 51,3% of patients, three-region involvement in 37,1%, four-region involvement in 3,4%, and five-region involvement in 2,0%. Stenoses of the common carotid artery were observed in 71% of patients, internal carotid artery — in 68%, lower limb artery — in 52%, and renal and mesenteric artery — in 8,3%. There were following diagnostic effectiveness of the ABI for detecting patients with lower limb artery stenosis was: sensitivity — 58,0%, specificity — 83,6%. The quality of antithrombotic and lipid-lowering therapy was insufficient.
Conclusion. In the overwhelming majority (95,6%) of patients with CAD in the KAMMA registry, PVD was revealed, with nearly half of the patients having involvement in three or more arterial zones. In the patient population with CAD, there should be an active effort to identify patients with PVD, using at least the ABI determination and active modern antithrombotic and lipid-lowering therapy according to current clinical guidelines.
About the Authors
G. P. ArutyunovRussian Federation
Moscow
Competing Interests:
None
E. I. Tarlovskaya
Russian Federation
Moscow; Nizhny Novgorod
Competing Interests:
None
A. G. Arutyunov
Armenia
Moscow; Yerevan
Competing Interests:
None
T. I. Batluk
Russian Federation
Moscow
Competing Interests:
None
N. A. Koziolova
Russian Federation
Perm
Competing Interests:
None
A. I. Chesnikova
Russian Federation
Rostov-on-Don
Competing Interests:
None
A. Y. Vaskin
Russian Federation
Moscow
Competing Interests:
None
D. S. Tokmin
Russian Federation
Angarsk
Competing Interests:
None
I. G. Bakulin
Russian Federation
Saint-Petersburg
Competing Interests:
None
O. L. Barbarash
Russian Federation
Kemerovo
Competing Interests:
None
N. U. Grigoryeva
Russian Federation
Nizhny Novgorod
Competing Interests:
None
I. V. Gubareva
Russian Federation
Samara
Competing Interests:
None
N. V. Izmozherova
Russian Federation
Yekaterinburg
Competing Interests:
None
U. K. Kamilova
Uzbekistan
Tashkent
Competing Interests:
None
S. G. Kechedzhieva
Russian Federation
Stavropol
Competing Interests:
None
Z. F. Kim
Russian Federation
Kazan
Competing Interests:
None
N. A. Koriagina
Russian Federation
Perm
Competing Interests:
None
S. V. Mironova
Russian Federation
Perm
Competing Interests:
None
N. P. Mitkovskaya
Belarus
Minsk
Competing Interests:
None
S. V. Nemirova
Russian Federation
Nizhny Novgorod
Competing Interests:
None
L. M. Nurieva
Russian Federation
Kazan
Competing Interests:
None
M. M. Petrova
Russian Federation
Krasnoyarsk
Competing Interests:
None
E. A. Polyanskaya
Russian Federation
Perm
Competing Interests:
None
A. P. Rebrov
Russian Federation
Saratov
Competing Interests:
None
A. V. Svarovskaya
Russian Federation
Tomsk
Competing Interests:
None
E. A. Smirnova
Russian Federation
Ryazan
Competing Interests:
None
A. B. Sugraliev
Kazakhstan
Almaty
Competing Interests:
None
Y. B. Khovaeva
Russian Federation
Perm
Competing Interests:
None
G. V. Shavkuta
Russian Federation
Rostov-on-Don
Competing Interests:
None
I. I. Shaposhnik
Russian Federation
Chelyabinsk
Competing Interests:
None
M. Y. Alieva
Uzbekistan
Tashkent
Competing Interests:
None
A. B. Almukhanova
Kazakhstan
Almaty
Competing Interests:
None
A. V. Aparkina
Russian Federation
Saratov
Competing Interests:
None
R. A. Bashkinov
Russian Federation
Moscow; Saint-Petersburg
Competing Interests:
None
L. N. Belousova
Russian Federation
Saint-Petersburg
Competing Interests:
None
E. I. Blokhina
Russian Federation
Nizhny Novgorod
Competing Interests:
None
V. O. Bochkareva
Russian Federation
Krasnoyarsk
Competing Interests:
None
M. V. Buianova
Russian Federation
Nizhny Novgorod
Competing Interests:
None
F. Y. Valikulova
Russian Federation
Nizhny Novgorod
Competing Interests:
None
A. D. Vende
Russian Federation
Tomsk
Competing Interests:
None
A. S. Galyavich
Russian Federation
Kazan
Competing Interests:
None
V. V. Genkel
Russian Federation
Chelyabinsk
Competing Interests:
None
E. V. Gorbunova
Russian Federation
Kemerovo
Competing Interests:
None
E. D. Gordeychuk
Russian Federation
Moscow
Competing Interests:
None
E. A. Grigorenko
Belarus
Minsk
Competing Interests:
None
E. V. Grigoryeva
Russian Federation
Saratov
Competing Interests:
None
I. L. Davydkin
Russian Federation
Samara
Competing Interests:
None
D. S. Evdokimov
Russian Federation
Saint-Petersburg
Competing Interests:
None
A. N. Ermilova
Russian Federation
Moscow
Competing Interests:
None
S. B. Zhangelova
Kazakhstan
Almaty
Competing Interests:
None
N. V. Zhdankina
Russian Federation
Nizhny Novgorod
Competing Interests:
None
E. I. Zheleznyak
Russian Federation
Rostov-on-Don
Competing Interests:
None
N. S. Ilyanok
Russian Federation
Ryazan
Competing Interests:
None
D. A. Kapsultanova
Kazakhstan
Almaty
Competing Interests:
None
N. A. Karoli
Russian Federation
Saratov
Competing Interests:
None
E. A. Kartashova
Russian Federation
Rostov-on-Don
Competing Interests:
None
A. S. Kuznetsova
Russian Federation
Chelyabinsk
Competing Interests:
None
A. T. Kumaritova
Russian Federation
Saint-Petersburg
Competing Interests:
None
N. A. Magdeeva
Russian Federation
Saratov
Competing Interests:
None
S. A. Makarov
Russian Federation
Kemerovo
Competing Interests:
None
E. S. Melnikov
Russian Federation
Moscow; Saint-Petersburg
Competing Interests:
None
M. V. Novikova
Russian Federation
Stavropol
Competing Interests:
None
I. A. Obukhova
Russian Federation
Krasnoyarsk
Competing Interests:
None
E. V. Ponomarenko
Russian Federation
Krasnodar
Competing Interests:
None
A. O. Rubanenko
Russian Federation
Samara
Competing Interests:
None
O. A. Rubanenko
Russian Federation
Samara
Competing Interests:
None
F. E. Rustamova
Kazakhstan
Almaty
Competing Interests:
None
V. A. Safronenko
Russian Federation
Rostov-on-Don
Competing Interests:
None
E. I. Suchkova
Russian Federation
Ryazan
Competing Interests:
None
A. I. Sycheva
Russian Federation
Perm
Competing Interests:
None
D. R. Tagaeva
Uzbekistan
Tashkent
Competing Interests:
None
M. A. Trubnikova
Russian Federation
Moscow; Sochi
Competing Interests:
None
T. P. Trunina
Russian Federation
Ryazan
Competing Interests:
None
A. G. Frolov
Russian Federation
Nizhny Novgorod
Competing Interests:
None
V. V. Khatlamadzhiyan
Russian Federation
Rostov-on-Don
Competing Interests:
None
Y. I. Khokhlova
Russian Federation
Saint-Petersburg
Competing Interests:
None
A. I. Chernyavina
Russian Federation
Perm
Competing Interests:
None
O. Y. Chizhova
Russian Federation
Saint-Petersburg
Competing Interests:
None
M. A. Shambatov
Russian Federation
Yekaterinburg
Competing Interests:
None
T. V. Shnyukova
Russian Federation
Rostov-on-Don
Competing Interests:
None
Y. V. Shchukin
Russian Federation
Samara
Competing Interests:
None
References
1. Anand SS, Aboyans V, Bosch J, et al.; XATOA Steering Committee. Identifying the highest risk vascular patients: Insights from the XATOA registry. Am Heart J. 2024;269:191-200. doi:10.1016/j.ahj.2024.01.001.
2. Gutierrez JA, Mulder H, Jones WS, et al. Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial. JAMA Netw Open. 2018;1(7):e185239. doi:10.1001/jamanetworkopen.2018.5239.
3. Ho V, Brown Johnson C, Ghanzouri I, et al. Physician- and Patient-Elicited Barriers and Facilitators to Implementation of a Machine Learning-Based Screening Tool for Peripheral Arterial Disease: Preimplementation Study With Physician and Patient Stakeholders. JMIR Cardio. 2023;7:e44732. doi:10.2196/44732.
4. Long C, Williams AO, McGovern AM, et al. Diversity in randomized clinical trials for peripheral artery disease: a systematic review. Int J Equity Health. 2024;23(1):29. doi:10.1186/s12939-024-02104-8.
5. Suárez C, Zeymer U, Limbourg T, et al.; REACH Registry Investigators. Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry. Vasc Med. 2010;15(4):259-65. doi:10.1177/1358863X10373299.
6. Criqui MH, Matsushita K, Aboyans V, et al.; American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Lifestyle and Cardiometabolic Health; Council on Peripheral Vascular Disease; and Stroke Council. Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association. Circulation. 2021;144(9):e171-e191. doi:10.1161/CIR.0000000000001005. Erratum in: Circulation. 2021;144(9):e193.
7. Batluk TI, Tarlovskaya EI, Arutyunov GP, et al. Clinical registry on patient population with Multifocal Atherosclerosis in the Russian Federation and Eurasian countries — KAMMA. Complex Issues of Cardiovascular Diseases. 2023;12(2):6-13. (In Russ.) doi:10.17802/2306-1278-2023-12-2-6-13.
8. Subherwal S, Bhatt DL, Li S, et al. Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2012;5(4):541-9. doi:10.1161/CIRCOUTCOMES.111.964379.
9. Kobo O, Contractor T, Mohamed MO, et al. Impact of pre-existent vascular and polyvascular disease on acute myocardial infarction management and outcomes: An analysis of 2 million patients from the National Inpatient Sample. Int J Cardiol. 2021;327:1-8. doi:10.1016/j.ijcard.2020.11.051.
10. Kobo O, Saada M, von Birgelen C, et al. Impact of multisite artery disease on clinical outcomes after percutaneous coronary intervention: an analysis from the e-Ultimaster registry. Eur Heart J Qual Care Clin Outcomes. 2023;9(4):417-26. doi:10.1093/ehjqcco/qcac043.
11. Barbarash LS, Sumin AN, Bezdenezhnykh AV, et al. Prevalence of polyvascular disease in patients with ischemic heart disease. Complex Issues of Cardiovascular Diseases. 2013;(3):4-11. (In Russ.) doi:10.17802/2306-1278-2013-3-4-11.
12. Blokhina AV, Ershova AI, Meshkov AN, et al. Lipid-lowering therapy: modern possibilities and real clinical practice. Cardiovascular Therapy and Prevention. 2022;21(8):3369. (In Russ.) doi:10.15829/1728-8800-2022-3369.
13. Stivalet O, Paisant A, Belabbas D, et al. Exercise testing criteria to diagnose lower extremity peripheral artery disease assessed by computed-tomography angiography. PLoS One. 2019;14:e0219082. doi:10.1371/journal.pone.0219082.
14. Herraiz-Adillo Á, Cavero-Redondo I, Álvarez-Bueno C, et al. The accuracy of toe brachial index and ankle brachial index in the diagnosis of lower limb peripheral arterial disease: a systematic review and meta-analysis. Atherosclerosis. 2020;315:81-92. doi:10.1016/j.atherosclerosis.2020.09.026.
15. Criqui MH, Vargas V, Denenberg JO, et al. Ethnicity and peripheral arterial disease: the San Diego Population Study. Circulation. 2005;112:2703-7. doi:10.1161/CIRCULATIONAHA.105.546507.
16. Russian Society of Cardiology (RSC) 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076. (In Russ.) doi:10.15829/29/1560-4071-2020-4076.
17. Fowkes FG, Murray GD, Butcher I, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300:197-208. doi:10.1001/jama.300.2.197.
18. Magnani G, Denegri A, Gurgoglione FL, et al. Dual Antiplatelet Therapy or Antiplatelet Plus Anticoagulant Therapy in Patients with Peripheral and Chronic Coronary Artery Disease: An Updated Review. J Clin Med. 2023;12(16):5284. doi:10.3390/jcm12165284.
19. Bonaca MP, Nault P, Giugliano RP, et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018;137(4):338-50. doi:10.1161/CIRCULATIONAHA.117.032235.
20. Eikelboom JW, Connolly SJ, Bosch J, et al.; COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377(14):1319-30. doi:10.1056/NEJMoa1709118.
21. Knuuti J, Wijns W, Saraste A, et al.; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-77. doi:10.1093/eurheartj/ehz425. Erratum in: Eur Heart J. 2020;41(44):4242.
22. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):e9-e119. doi:10.1161/CIR.0000000000001168. Erratum in: Circulation. 2023;148(13):e148. Erratum in: Circulation. 2023;148(23):e186.
23. Hess CN, Rogers RK, Wang TY, et al. Major adverse limb events and 1-year outcomes after peripheral artery revascularization. J Am Coll Cardiol. 2018;72:999-1011. doi:10.1016/j.jacc.2018.06.041.
Supplementary files
- 95,6% of patients with coronary artery disease have atherosclerosis involving different locations, and nearly half of them — three or more zones, the most common of which are the common and internal carotid arteries and arterial lesions of the extremities.
- 72,8% of individuals with polyvascular disease experienced major cardiovascular events, including myocardial infarction, ischemic stroke, and transient ischemic attack.
- Despite the very high cardiovascular risk in patients with coronary artery disease and polyvascular disease, the quality of antithrombotic and hypolipidemic therapy is insufficient.
Review
For citations:
Arutyunov G.P., Tarlovskaya E.I., Arutyunov A.G., Batluk T.I., Koziolova N.A., Chesnikova A.I., Vaskin A.Y., Tokmin D.S., Bakulin I.G., Barbarash O.L., Grigoryeva N.U., Gubareva I.V., Izmozherova N.V., Kamilova U.K., Kechedzhieva S.G., Kim Z.F., Koriagina N.A., Mironova S.V., Mitkovskaya N.P., Nemirova S.V., Nurieva L.M., Petrova M.M., Polyanskaya E.A., Rebrov A.P., Svarovskaya A.V., Smirnova E.A., Sugraliev A.B., Khovaeva Y.B., Shavkuta G.V., Shaposhnik I.I., Alieva M.Y., Almukhanova A.B., Aparkina A.V., Bashkinov R.A., Belousova L.N., Blokhina E.I., Bochkareva V.O., Buianova M.V., Valikulova F.Y., Vende A.D., Galyavich A.S., Genkel V.V., Gorbunova E.V., Gordeychuk E.D., Grigorenko E.A., Grigoryeva E.V., Davydkin I.L., Evdokimov D.S., Ermilova A.N., Zhangelova S.B., Zhdankina N.V., Zheleznyak E.I., Ilyanok N.S., Kapsultanova D.A., Karoli N.A., Kartashova E.A., Kuznetsova A.S., Kumaritova A.T., Magdeeva N.A., Makarov S.A., Melnikov E.S., Novikova M.V., Obukhova I.A., Ponomarenko E.V., Rubanenko A.O., Rubanenko O.A., Rustamova F.E., Safronenko V.A., Suchkova E.I., Sycheva A.I., Tagaeva D.R., Trubnikova M.A., Trunina T.P., Frolov A.G., Khatlamadzhiyan V.V., Khokhlova Y.I., Chernyavina A.I., Chizhova O.Y., Shambatov M.A., Shnyukova T.V., Shchukin Y.V. Peculiarities of polyvascular disease and the diagnostic significance of the ankle-brachial index in patients with coronary artery disease: results from the real-world registry KAMMA (Clinical registry on patient population with polyvascular disease in the Russian Federation and Eurasian countries). Russian Journal of Cardiology. 2024;29(4):5837. (In Russ.) https://doi.org/10.15829/1560-4071-2024-5837. EDN: AZMGQZ